Clinical Library

Study Goal: Quality assurance initiative to determine the minimum number of calcification-containing stereotactic biopsy specimens sufficient for pathologic diagnosis and immunohistochemistry (IHC) in cases of malignancy.   Please visit PubMed for the full text article.  

This article is intended to compare case delays in all patients undergoing breast conserving surgery (BCS) with wire localization in 2017 with all patients undergoing BCS with a radiofrequency identification tag system.   Please visit PubMed for the full text article.  

  A prospective, single-center pilot study evaluated the effectiveness of the FDA-cleared Radiofrequency Identification Localization System (RFLS).   Please visit PubMed for the full text article.  

The article is intended to assess the feasibility of using RFID technology to localize nonpalpable breast lesions.   Please visit PubMed for the full text article.  

The article is intended to assess the safety and performance of a radiofrequency identification tag to localize nonpalpable breast lesions for surgical excision. Please visit PubMed for the full text article.

Authored by Alejandro Tejerina, MD, this white paper will cover the advances in breast screening technology, most notably tomosynthesis, are enabling us to visualize subtle lesions, not previously seen on 2D images. However, the improvements in imaging quality and specificity provided by tomosynthesis pose challenges to our protocols for the management of lesions identified with the technology.    

Authored by Lars Grimm, MD, MHS, this white paper will cover the benefits of tomosynthesis guided biopsy in comparison to traditional two-dimensional mammographic guided biopsies. Specifically, this paper will apply to the Hologic Affirm® Prone Biopsy System and the Affirm® Breast Biopsy Guidance System for the Selenia® Dimensions® and 3Dimensions™ mammography Systems.  

This prospective study has two objectives. The first objective is compare single reading of tomosynthesis examinations to double reading of 2D examinations. The second objective is to assess whether 2D FFDM have any added value when using synthesized 2D mammography (s2D) together with digital breast Tomosynthesis. Please visit PubMed for the full text article.

The article first compares the sensitivity and specificity of contrast-enhanced digital mammography (CEDM) to breast MRI. The next portion lays the foundation for CEDM as a diagnostic alternative to breast MRI based on cost, equipment, and patient access to these modalities.   Please visit PubMed for the full text article.

Authored by Andrew Smith, Ph.D, this white paper will cover the history of breast compression and approaches Hologic employs to reduce discomfort during mammography imaging. In particular, it will discuss the newest product in the Hologic portfolio, the SmartCurve™ breast stabilization system, designed to greatly improve comfort during breast compression, especially for women who experience pain using conventional flat compression paddles.  

The purpose of this study was to evaluate and compare the clinical performance of synthesized 2D (s2D) and DBT, FFDM and DBT to and FFDM alone, in a large community based screening population. The group analyzed outcomes performance, including recall rates, positive predictive values, cancer detection rate among others.   Please visit PubMed for the full text article.

The purpose of this study was to evaluate the role of contrast-enhanced digital mammography (CEDM) in determining the surgical management of breast cancer. When breast MRI (bMRI) was also performed, CEDM results were compared with bMRI. Please visit PubMed for the full text article.